pubmed-article:8124690 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:8124690 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
pubmed-article:8124690 | lifeskim:mentions | umls-concept:C0553580 | lld:lifeskim |
pubmed-article:8124690 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
pubmed-article:8124690 | lifeskim:mentions | umls-concept:C0542341 | lld:lifeskim |
pubmed-article:8124690 | lifeskim:mentions | umls-concept:C0439851 | lld:lifeskim |
pubmed-article:8124690 | lifeskim:mentions | umls-concept:C0037791 | lld:lifeskim |
pubmed-article:8124690 | lifeskim:mentions | umls-concept:C1552596 | lld:lifeskim |
pubmed-article:8124690 | lifeskim:mentions | umls-concept:C1947931 | lld:lifeskim |
pubmed-article:8124690 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:8124690 | pubmed:dateCreated | 1994-4-12 | lld:pubmed |
pubmed-article:8124690 | pubmed:abstractText | A selection of 16 monoclonal antibodies has been produced against a fresh Ewing's sarcoma (ES) tumor mixed with a permanent ES cell line. The majority of antibodies identify an 80-kDa molecule, which is not detected on healthy tissues except on certain cultured monocytes. One antibody recognizes the CD2 ligand MIC2 and 2 antibodies (numbers 13 and 16) define a higher-molecular-mass antigen. Antibody 16 is also expressed on mesenchymal fibroblasts of bone marrow or fetal origin. Tumor-specific antigen expression is potentially linked to the chromosome 22 abnormality described in Ewing's sarcoma, products altered expression in tumors with the chromosome 11/22 translocation has not been shown. The putative chimeric protein on chromosome 11 is apparently not expressed to a great extent, as tested by Northern blotting; however, the fusion protein initiated on chromosome 22 and ending on chromosome 11 is readily seen on Northern blots. The altered expression of a number of cellular genes in addition to a novel gene product(s) originating from translocation events were expected to be identified by monoclonal antibodies selected by their unique binding pattern to Ewing's sarcoma (ES) cells. | lld:pubmed |
pubmed-article:8124690 | pubmed:language | eng | lld:pubmed |
pubmed-article:8124690 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8124690 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:8124690 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8124690 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8124690 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8124690 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8124690 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8124690 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:8124690 | pubmed:month | Mar | lld:pubmed |
pubmed-article:8124690 | pubmed:issn | 0340-7004 | lld:pubmed |
pubmed-article:8124690 | pubmed:author | pubmed-author:BorchardFF | lld:pubmed |
pubmed-article:8124690 | pubmed:author | pubmed-author:GöbelUU | lld:pubmed |
pubmed-article:8124690 | pubmed:author | pubmed-author:JürgensHH | lld:pubmed |
pubmed-article:8124690 | pubmed:author | pubmed-author:SchneiderE... | lld:pubmed |
pubmed-article:8124690 | pubmed:author | pubmed-author:ShiL RLR | lld:pubmed |
pubmed-article:8124690 | pubmed:author | pubmed-author:EichelbauerDD | lld:pubmed |
pubmed-article:8124690 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:8124690 | pubmed:volume | 38 | lld:pubmed |
pubmed-article:8124690 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:8124690 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:8124690 | pubmed:pagination | 208-13 | lld:pubmed |
pubmed-article:8124690 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
pubmed-article:8124690 | pubmed:meshHeading | pubmed-meshheading:8124690-... | lld:pubmed |
pubmed-article:8124690 | pubmed:meshHeading | pubmed-meshheading:8124690-... | lld:pubmed |
pubmed-article:8124690 | pubmed:meshHeading | pubmed-meshheading:8124690-... | lld:pubmed |
pubmed-article:8124690 | pubmed:meshHeading | pubmed-meshheading:8124690-... | lld:pubmed |
pubmed-article:8124690 | pubmed:meshHeading | pubmed-meshheading:8124690-... | lld:pubmed |
pubmed-article:8124690 | pubmed:meshHeading | pubmed-meshheading:8124690-... | lld:pubmed |
pubmed-article:8124690 | pubmed:meshHeading | pubmed-meshheading:8124690-... | lld:pubmed |
pubmed-article:8124690 | pubmed:meshHeading | pubmed-meshheading:8124690-... | lld:pubmed |
pubmed-article:8124690 | pubmed:meshHeading | pubmed-meshheading:8124690-... | lld:pubmed |
pubmed-article:8124690 | pubmed:meshHeading | pubmed-meshheading:8124690-... | lld:pubmed |
pubmed-article:8124690 | pubmed:meshHeading | pubmed-meshheading:8124690-... | lld:pubmed |
pubmed-article:8124690 | pubmed:meshHeading | pubmed-meshheading:8124690-... | lld:pubmed |
pubmed-article:8124690 | pubmed:year | 1994 | lld:pubmed |
pubmed-article:8124690 | pubmed:articleTitle | Specificity and function of monoclonal antibodies directed against Ewing sarcoma cells. | lld:pubmed |
pubmed-article:8124690 | pubmed:affiliation | Immunology Laboratory, Institute of Blood Coagulation and Transfusion Medicine, University of Düsseldorf, Germany. | lld:pubmed |
pubmed-article:8124690 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:8124690 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |